John G Ullman & Associates Inc. Sells 105 Shares of Danaher Co. (NYSE:DHR)

John G Ullman & Associates Inc. lessened its holdings in Danaher Co. (NYSE:DHR) by 10.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 914 shares of the conglomerate’s stock after selling 105 shares during the period. John G Ullman & Associates Inc.’s holdings in Danaher were worth $228,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Public Sector Pension Investment Board grew its holdings in Danaher by 15.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 73,391 shares of the conglomerate’s stock valued at $18,208,000 after buying an additional 9,798 shares in the last quarter. Okabena Investment Services Inc. purchased a new stake in Danaher during the 3rd quarter valued at approximately $686,000. American Century Companies Inc. grew its holdings in Danaher by 19.4% during the 3rd quarter. American Century Companies Inc. now owns 1,735,073 shares of the conglomerate’s stock valued at $430,472,000 after buying an additional 282,089 shares in the last quarter. Wellington Management Group LLP grew its holdings in Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Finally, Financial Insights Inc. purchased a new stake in Danaher during the 3rd quarter valued at approximately $371,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 148,783 shares of company stock worth $37,536,717. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on DHR shares. Bank of America raised their target price on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Citigroup lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Barclays lifted their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. TD Cowen lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Jefferies Financial Group initiated coverage on shares of Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $268.67.

Danaher Stock Up 0.2 %

Shares of DHR traded up $0.57 during mid-day trading on Friday, hitting $246.84. 213,873 shares of the company traded hands, compared to its average volume of 2,841,726. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $182.83 billion, a PE ratio of 41.74, a price-to-earnings-growth ratio of 3.70 and a beta of 0.83. The business has a 50 day moving average of $255.05 and a 200 day moving average of $247.31.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the company posted $2.36 earnings per share. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. Equities research analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.